Hexima Limited

About:

Hexima develops plant-derived proteins and peptides as human antifungal therapeutics.

Top Investors: Government of South Australia

Description:

Hexima is a clinical-stage anti-infectives biotechnology company that is developing plant defensin peptides for human therapeutic applications. They provide treatment for toenail fungal infections and onychomycosis.

Total Funding Amount:

1.38M AUD

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sydney, New South Wales, Australia

Founded Date:

1998-01-01

Contact Email:

registrars(AT)linkmarketservices.com.au

Founders:

Adrienne Clarke, Marilyn Anderson, Robyn Heath

Number of Employees:

11-50

Last Funding Date:

2009-07-09

IPO Status:

Public

Industries: